NIH Shift Away from Animal-Only Research Signals a Major Opportunity for Organoids

Abstract

In April 2025, the U.S. National Institutes of Health (NIH) announced a landmark shift that will reshape biomedical  research for decades: the agency will no longer issue Notices of Funding Opportunities (NOFOs) that rely exclusively on  animal models. Instead, all future funding calls must include—or explicitly permit—the use of non-animal methods  (NAMs), including organoids, microphysiological systems, computational models, human-derived tissues, and  advanced in vitro approaches. This policy, formalized at the first FDA–NIH “Workshop on Reducing Animal Testing” on  July 7, 2025, marks an unprecedented reorientation of federal funding priorities toward human-relevant, ethical, and  translationally predictive model systems. For the organoid field, the implications are vast: expanded funding,  accelerated standardization, infrastructure scaling, enhanced regulatory relevance, and deeper integration into drug  development and precision medicine. Yet the shift also presents scientific and practical challenges, including issues of  reproducibility, biological complexity, and global regulatory acceptance. This article analyzes the motivations behind  the NIH decision, its transformative significance for organoid science, the challenges ahead, and the role of standards  such as ISoOR-ISOB and the newly funded Standardized Organoid Modeling (SOM) Center in shaping the next era of  biomedical research.